Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is how Agenus (AGEN) and Ensign Group (ENSG) have performed compared to their sector so far this year.
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.